Literature DB >> 16998755

Therapy of immune neuropathies with intravenous immunoglobulins.

Ralf Gold1, Bernd C Kieseier.   

Abstract

Autoimmune-mediated disorders belong to the main causes of neuropathies worldwide. During recent years much progress has been achieved in the understanding of the underlying pathomechanisms, associated with implications for therapeutic approaches. Here we will briefly review the pathogenesis and discuss treatment options of the Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, and neuropathies associated with paraproteinemias. In most of these disease entities intravenous immunoglobulins play a major role as effective and safe treatment options.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16998755     DOI: 10.1007/s00415-006-5008-9

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  39 in total

1.  Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome.

Authors:  Brigitte Buchwald; Raheleh Ahangari; Andreas Weishaupt; Klaus V Toyka
Journal:  Ann Neurol       Date:  2002-06       Impact factor: 10.422

2.  A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group.

Authors:  F G van der Meché; P I Schmitz
Journal:  N Engl J Med       Date:  1992-04-23       Impact factor: 91.245

3.  Guillain-Barré syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b Antibodies in rabbits.

Authors:  C W Ang; M A De Klerk; H P Endtz; B C Jacobs; J D Laman; F G van der Meché; P A van Doorn
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

4.  Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  J R Mendell; R J Barohn; M L Freimer; J T Kissel; W King; H N Nagaraja; R Rice; W W Campbell; P D Donofrio; C E Jackson; R A Lewis; M Shy; D M Simpson; G J Parry; M H Rivner; C A Thornton; M B Bromberg; R Tandan; Y Harati; M J Giuliani
Journal:  Neurology       Date:  2001-02-27       Impact factor: 9.910

5.  Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies.

Authors:  Susanne Renaud; Michael Gregor; Peter Fuhr; Delia Lorenz; Günther Deuschl; Alois Gratwohl; Andreas J Steck
Journal:  Muscle Nerve       Date:  2003-05       Impact factor: 3.217

6.  A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy.

Authors:  M C Dalakas; R H Quarles; R G Farrer; J Dambrosia; S Soueidan; D P Stein; E Cupler; E A Sekul; C Otero
Journal:  Ann Neurol       Date:  1996-11       Impact factor: 10.422

7.  Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity.

Authors:  R S Fujinami; M B Oldstone
Journal:  Science       Date:  1985-11-29       Impact factor: 47.728

8.  Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group.

Authors:  L H Visser; F G Van der Meché; P A Van Doorn; J Meulstee; B C Jacobs; P G Oomes; R P Kleyweg; J Meulstee
Journal:  Brain       Date:  1995-08       Impact factor: 13.501

9.  Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study.

Authors:  M Vermeulen; P A van Doorn; A Brand; P F Strengers; F G Jennekens; H F Busch
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-01       Impact factor: 10.154

10.  Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.

Authors:  R D Hadden; D R Cornblath; R A Hughes; J Zielasek; H P Hartung; K V Toyka; A V Swan
Journal:  Ann Neurol       Date:  1998-11       Impact factor: 10.422

View more
  5 in total

Review 1.  Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies.

Authors:  Verena I Leussink; Hans-Peter Hartung; Bernd C Kieseier; Mark Stettner
Journal:  Ther Adv Neurol Disord       Date:  2016-04-06       Impact factor: 6.570

Review 2.  Immune-mediated neuropathies.

Authors:  Bernd C Kieseier; Emily K Mathey; Claudia Sommer; Hans-Peter Hartung
Journal:  Nat Rev Dis Primers       Date:  2018-10-11       Impact factor: 52.329

Review 3.  [The significance of intravenous immunoglobulin in treatment of immune-mediated polyneuropathies].

Authors:  M Stangel; H-P Hartung; R Gold; B C Kieseier
Journal:  Nervenarzt       Date:  2009-06       Impact factor: 1.214

4.  MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.

Authors:  Peizhong Mao; Maria Manczak; Ulziibat P Shirendeb; P Hemachandra Reddy
Journal:  Biochim Biophys Acta       Date:  2013-09-19

5.  Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy.

Authors:  Mark Stettner; Lena Hinrichs; Rainer Guthoff; Silja Bairov; Ioannis N Petropoulos; Clemens Warnke; Hans-Peter Hartung; Rayaz A Malik; Bernd C Kieseier
Journal:  Ann Clin Transl Neurol       Date:  2015-12-28       Impact factor: 4.511

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.